We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

ECG Helps Predict Defibrillator Mortality Benefit

By HospiMedica International staff writers
Posted on 18 Sep 2019
A new study suggests an electrocardiogram (ECG) that measures periodic repolarization dynamics (PRD) can help identify patients most likely to benefit from an implantable cardioverter defibrillator (ICD).

Researchers at Munich Technical University (TUM; Germany), Ludwig-Maximilians-Universität (LMU; Munich, Germany), and University Medical Center Göttingen (Germany) conducted a prospective study to examine if PRD, a novel marker of sympathetic-activity-associated repolarization instability, could be used to identify electrically vulnerable patients who would benefit from prophylactic implantation of ICDs.

To do so, they tracked 1,371 patients who met the current criteria for an ICD between May 12, 2014, and September 7, 2018. Of the study population, 968 actually underwent the procedure, while the other 403 patients did not receive an ICD. PRD from 24-hour Holter recordings were assessed blindly in patients the day before ICD implantation, or on the day of study enrolment in patients who were conservatively managed. The primary endpoint was all-cause mortality.

The results showed that during follow-up, 14% of patients died in the ICD group and 16% patients died in the control group; a 43% reduction in mortality in the ICD group was identified, when compared to patients in the control group. PRD significantly predicted the treatment effect of ICDs on mortality (43%), with benefits associated with implantation greater in patients with PRD of 75 degrees or higher (75%) than in those with PRD values below 7.5 degrees (31%). The study was published on September 1, 2019, in The Lancet.

“PRD could become an important decision making tool for physicians. With the additional information, patients who would probably not benefit from a defibrillator could be spared the risk of an implant. Instead, we could focus on those whose lives would likely be extended by the device,” said study co-author Professor Georg Schmidt, MD, head of the Biosignal Processing Working Group at TUM. “The results will first have to be confirmed in further studies, however, before they can be included in medical treatment guidelines.”

PRD refers to low-frequency (≤0.1Hz) modulations of cardiac repolarization instability. Physiological and experimental studies have indicated that PRD correlates with efferent sympathetic nerve activity, which clusters in low-frequency bursts and increases by physiological provocations that lead to enhancement of sympathetic activity, whereas it is suppressed by pharmacological b-blockade. Increased PRD under resting conditions is a strong predictor of mortality in post myocardial infarction patients, particularly in those with a preserved left ventricular ejection fraction (LVEF) higher than 35%.

Related Links:
Munich Technical University
Ludwig-Maximilians-Universität
University Medical Center Göttingen

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Ureteral Dilatation Balloon
Dornier Equinox

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more